MD
Therapeutic Areas
Rafael Holdings Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CPI-613 (devimistat) + FOLFIRINOX | Metastatic Pancreatic Adenocarcinoma | Phase 3 |
| CPI-613 (devimistat) + Cytarabine/Mitoxantrone | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 3 |
| CPI-613 (devimistat) + Modified FOLFIRINOX | Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 |
| CPI-613 (devimistat) + Hydroxychloroquine | Pancreatic Cancer | Phase 1/2 |
| CPI-613 (devimistat) | T-cell Lymphomas (Peripheral, Cutaneous) | Phase 1 |
| CPI-613 (devimistat) + Bendamustine + Rituximab | Relapsed or Refractory Mantle Cell Lymphoma | Phase 1 |